Want to see HK:2228 full AI Analyst Report?
QuantumPharm, Inc. (2228) Ratios
QuantumPharm, Inc. Ratios
HK:2228's free cash flow for Q2 2026 was $-418.82M. For the 2026 fiscal year, HK:2228's free cash flow was decreased by $-49.10M and operating cash flow was $-369.72M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.77 | 11.85 | 9.90 | 18.20 | 24.37 |
| Quick Ratio | 14.52 | 11.85 | 9.86 | 18.20 | 24.37 |
| Cash Ratio | 5.13 | 4.17 | 2.39 | 2.91 | 21.90 |
| Solvency Ratio | 0.30 | -3.95 | -0.16 | -0.14 | -0.26 |
| Operating Cash Flow Ratio | -0.28 | -1.71 | -1.91 | -2.17 | -1.58 |
| Short-Term Operating Cash Flow Coverage | -0.71 | -9.22 | -9.46 | -11.92 | -11.39 |
| Net Current Asset Value | $ 6.68B | $ 2.95B | $ -8.30B | $ -6.03B | $ -4.07B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.03 | 2.76 | 2.19 | 1.79 |
| Debt-to-Equity Ratio | 0.05 | 0.04 | -1.52 | -1.77 | -2.17 |
| Debt-to-Capital Ratio | 0.05 | 0.04 | 2.93 | 2.29 | 1.85 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 3.07 | 2.33 | 1.88 |
| Financial Leverage Ratio | 1.09 | 1.10 | -0.55 | -0.81 | -1.21 |
| Debt Service Coverage Ratio | 1.22 | -10.76 | -25.51 | -10.93 | -80.89 |
| Interest Coverage Ratio | -54.40 | -101.26 | -75.44 | -91.42 | -83.76 |
| Debt to Market Cap | 0.01 | 0.00 | 0.85 | 5.18 | 4.65 |
| Interest Debt Per Share | 0.12 | 0.08 | 4.57 | 2.78 | 2.30 |
| Net Debt to EBITDA | -8.47 | 1.61 | -5.82 | -22.74 | -2.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.67% | 46.33% | 27.66% | 49.56% | 52.21% |
| EBIT Margin | 18.03% | -268.27% | -1087.46% | -1074.49% | -3397.76% |
| EBITDA Margin | 32.43% | -236.98% | -1017.67% | -292.74% | -3360.92% |
| Operating Profit Margin | -63.50% | -256.80% | -414.12% | -393.93% | -476.81% |
| Pretax Profit Margin | 16.86% | -568.57% | -1092.95% | -1078.80% | -3403.45% |
| Net Profit Margin | 15.42% | -569.23% | -1097.57% | -1078.72% | -3403.38% |
| Continuous Operations Profit Margin | 16.77% | -568.57% | -1092.95% | -1078.80% | -3403.45% |
| Net Income Per EBT | 91.42% | 100.11% | 100.42% | 99.99% | 100.00% |
| EBT Per EBIT | -26.56% | 221.41% | 263.92% | 273.86% | 713.80% |
| Return on Assets (ROA) | 1.18% | -34.83% | -47.79% | -33.33% | -48.78% |
| Return on Equity (ROE) | 1.28% | -38.26% | 26.34% | 27.00% | 59.22% |
| Return on Capital Employed (ROCE) | -5.11% | -16.79% | -19.48% | -12.76% | -7.09% |
| Return on Invested Capital (ROIC) | -4.98% | -16.45% | -18.87% | -13.15% | -6.96% |
| Return on Tangible Assets | 1.21% | -34.89% | -47.89% | -33.38% | -48.83% |
| Earnings Yield | 0.38% | -14.07% | -15.07% | -79.70% | -128.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.05 | 1.95 | 4.53 | 3.52 | 2.04 |
| Payables Turnover | 3.89 | 8.86 | 9.24 | 4.81 | 2.84 |
| Inventory Turnover | 1.86 | 0.00 | 10.43 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.14 | 0.65 | 0.31 | 0.33 | 0.22 |
| Asset Turnover | 0.08 | 0.06 | 0.04 | 0.03 | 0.01 |
| Working Capital Turnover Ratio | 0.16 | 0.00 | 0.06 | 0.04 | 0.04 |
| Cash Conversion Cycle | 174.75 | 145.82 | 76.07 | 27.98 | 49.96 |
| Days of Sales Outstanding | 72.27 | 187.02 | 80.58 | 103.83 | 178.53 |
| Days of Inventory Outstanding | 196.21 | 0.00 | 34.98 | 0.00 | 0.00 |
| Days of Payables Outstanding | 93.73 | 41.20 | 39.50 | 75.85 | 128.58 |
| Operating Cycle | 268.48 | 187.02 | 115.56 | 103.83 | 178.53 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.04 | -0.25 | -0.23 | -0.13 | -0.07 |
| Free Cash Flow Per Share | -0.05 | -0.28 | -0.29 | -0.18 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | -2.31 | -8.24 | -4.34 | -2.16 | -1.55 |
| Capital Expenditure Coverage Ratio | -2.31 | -8.24 | -4.34 | -2.16 | -1.55 |
| Operating Cash Flow Coverage Ratio | -0.31 | -3.22 | -0.05 | -0.05 | -0.03 |
| Operating Cash Flow to Sales Ratio | -0.18 | -1.80 | -3.25 | -3.22 | -4.04 |
| Free Cash Flow Yield | -0.62% | -4.98% | -5.50% | -34.78% | -25.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 266.36 | -7.11 | -6.64 | -1.25 | -0.78 |
| Price-to-Sales (P/S) Ratio | 41.11 | 40.47 | 72.83 | 13.53 | 26.51 |
| Price-to-Book (P/B) Ratio | 3.42 | 2.72 | -1.75 | -0.34 | -0.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -160.72 | -20.09 | -18.19 | -2.87 | -3.99 |
| Price-to-Operating Cash Flow Ratio | -230.19 | -22.52 | -22.38 | -4.21 | -6.56 |
| Price-to-Earnings Growth (PEG) Ratio | -2.56 | 0.00 | -0.20 | 0.04 | -0.00 |
| Enterprise Value Multiple | 118.26 | -15.47 | -12.97 | -27.36 | -2.83 |
| Enterprise Value | 29.99B | 9.76B | 23.03B | 10.68B | 5.97B |
| EV to EBITDA | 118.26 | -15.47 | -12.97 | -27.36 | -2.83 |
| EV to Sales | 38.36 | 36.65 | 132.03 | 80.10 | 95.14 |
| EV to Free Cash Flow | -149.98 | -18.19 | -32.98 | -17.01 | -14.31 |
| EV to Operating Cash Flow | -214.80 | -20.40 | -40.57 | -24.89 | -23.55 |
| Tangible Book Value Per Share | 2.43 | 2.08 | -3.00 | -1.56 | -1.06 |
| Shareholders’ Equity Per Share | 2.48 | 2.06 | -3.01 | -1.56 | -1.06 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.00 | 0.00 | -0.05 | 0.01 |
| Revenue Per Share | 0.21 | 0.14 | 0.07 | 0.04 | 0.02 |
| Net Income Per Share | 0.03 | -0.79 | -0.79 | -0.42 | -0.63 |
| Tax Burden | 0.91 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.94 | 2.12 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.71 | 1.57 | 2.76 | 2.69 | 3.39 |
| SG&A to Revenue | 0.61 | 2.07 | 0.31 | 0.42 | 0.87 |
| Stock-Based Compensation to Revenue | 0.00 | 0.51 | 0.51 | 0.33 | 0.36 |
| Income Quality | -1.16 | 0.32 | 0.30 | 0.30 | 0.12 |
Currency in CNY